Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Nxera Earns US$4.8 Million Milestone as Centessa’s OX2R Drug Advances
Nxera Pharma said on July 4 that it will receive a US$4.8 million milestone payment under its R&D collaboration with Centessa Pharmaceuticals, following the launch of a PI trial for the investigational orexin receptor 2 (OX2R) agonist ORX142. The payment…
To read the full story
Related Article
- Nxera Gets US$1.8 Million Early-Stage Milestone from Centessa
February 13, 2026
- Nxera Snags US$3.6 Million Early-Stage Milestone on OX2R Agonist
January 14, 2026
- Nxera Gets US$4.6 Million Milestone over Centessa’s OX2R Agonist
May 31, 2024
BUSINESS
- Alexion CEO Calls Japan “Special” for Rare Disease Drug Development
July 9, 2026
- AstraZeneca CSO Urges Global Drug Price “Rebalancing” amid MFN Push
July 8, 2026
- JB to Build New Plant in Hokkaido to Double Ig Production
July 8, 2026
- Padcev/Keytruda Accepted for China Review in Perioperative MIBC
July 8, 2026
- Japan Ethical Drug Sales Fall 1.1% in May: Crecon
July 8, 2026
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…